Indivior has dosed the first subject in a Phase II clinical trial of INDV-2000 for individuals with opioid use disorder (OUD).

The double-blind, placebo-controlled, randomised, dose-ranging study aims to evaluate the safety and efficacy of the asset over a three-month period in treatment-seeking participants with moderate to severe OUD.

It will enrol individuals who have recently initiated or completed short-term medically supervised opioid withdrawal using transmucosal (TM) buprenorphine and are considering a non-opioid treatment alternative.

On the first day, participants will be randomised to receive either INDV-2000 or a placebo alongside TM buprenorphine until day seven.

Following this, INDV-2000 or a placebo will be administered independently from day eight onwards.

The randomised treatment period will last for three months or until the participant’s final study visit.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The treatment period may also conclude if a participant requires buprenorphine rescue therapy due to a relapse into illicit opioid use.

INDV-2000, an oral orexin-1 receptor (OX1R) antagonist, has shown promising results in rodent models of addiction and has a safety profile that is suitable for human clinical trials.

This study is supported by a grant under the NIH-HEAL initiative, which is dedicated to the clinical development of new treatments for addiction.

Indivior chief scientific officer Christian Heidbreder said: “INDV-2000 provides Indivior with a unique opportunity to further address unmet patient needs in the treatment of OUD, with potentially the first non-opioid orexin-targeted therapy.

“By providing a potential therapeutic option for patients who might benefit from a non-opioid alternative, INDV-2000 may broaden the spectrum of care for OUD treatment.

“This milestone highlights Indivior’s commitment to developing a wider range of therapeutics in both the opioid and non-opioid treatment category, ultimately providing more choices for the patient.”